Lumida
/MDAI
⌘K
MDAI

MDAI

MDAI
$1.57USD↑+0.97%+0.01 today

MARKET CAP

50.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$3

The case for & against

Bull & Bear analysis

Bearish

Spectral AI (NASDAQ: MDAI) is an emerging player in the medical diagnostics sector, particularly focused on innovative imaging solutions for burn care through its proprietary DeepView system. Following its recent FDA de novo clearance, the company is transitioning from a development-focused stage to a commercial entity, with significant aspirations to establish a foothold in both domestic and international markets. Its emphasis on AI integration into medical imaging underscores a broader theme around healthcare innovation and technology adoption.

Bull says

  • ↑FDA de novo clearance for DeepView system drives first-mover advantage.
  • ↑2026 revenue guidance of $18.5M (ex-DeepView) underpins growth outlook.
  • ↑$60M BARDA funding and $14M cash bolster liquidity.
  • ↑Strategic burn community ties accelerate early DeepView deployments.
  • ↑Planned sales force expansion aligns with anticipated demand.
  • ↑Adequate short-term liquidity and low volatility sensitivity support stability.

Bear says

  • ↓Net loss narrowed to $4.2M in Q2 2026, but still unsustainable.
  • ↓Operating expenses rose 23% YoY to $5.4M without DeepView revenues.
  • ↓Market penetration hurdles in centers lacking relationships may delay sales.
  • ↓High short interest signals investor skepticism on stock outlook.
  • ↓Weak profitability factors and distressed book-to-price hint at value erosion.
  • ↓Long debt schedule of $14.9M to March 2028 adds leverage risk.

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-15-2025neutral

Transcript signals

Bull points

  • We had a strong start to the year with significant accomplishments in the areas of product advancement and deployment, clinical studies and executive appointments. We also strengthened our financial profile and created a well-defined cash runway to support our growth initiatives.
  • As previously announced, in February 2024, we received UKCA authorization to commence sales of DeepView AI-Burn in the U.K. We are excited to share the deployment of DeepView systems at 3 U.K. hospitals; Royal Victoria Infirmary in Newcastle, Stoke Mandeville Hospital in Buckinghamshire, and Broomfield Hospital in Essex.
  • After a period of customer evaluation, we expect to initiate commercial transactions in the second half of this year. While we do not expect these transactions to represent a significant contribution to revenues in 2024, we are pleased to begin commercial activities.

Bear points

  • We trimmed our net loss for the quarter to $3.2 million or $0.19 per share as compared to a net loss of $3.6 million or $0.27 per share last year.
  • ramp-up period in the first quarter was, as I said, just a touch slower than what we had anticipated, but we're very pleased with where we are to date and the current momentum. That being said, we do think the revenue would be a little bit back-ended to the second half of the year.
  • We don't see any capacity constraints relative to getting these devices out. We think we can work with our -- well, we know we can work with our manufacturing partner to produce the devices needed to not only distribute to the locations anticipated within the BARDA contract, but to others, I do think it would be something relatively parallel.
Read full transcript analysis ›